Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
Myasthenia gravis (MG) is a complex autoimmune neuromuscular disorder, and the role of lipid metabolism dysregulation in MG pathogenesis remains unclear. This study aimed to investigate the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development by integrating single-cel…
A case report of sporadic Creutzfeldt-Jakob disease presenting with progressive opsoclonus-myoclonus-ataxia-Plus (OMAS-Plus) phenotype.
Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive prion disorder whose heterogeneous manifestations may overlap with potentially treatable neurological conditions. We report an atypical sCJD phenotype dominated by progressive dysarthria and an opsoclonus-myoclonus-ataxia-plus (OMAS-…
Primigravida with generalized myasthenia gravis leading to caesarean section delivery: a case report.
Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, characterized by fluctuating muscle weakness. Pregnancy in women with MG poses unique challenges, as physiological and immunological changes may influence disease activity and obstetric outcomes. A 25-year-…
Anti-C2-mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis.
Acetylcholine receptor antibody-positive myasthenia gravis (AChR-MG) is a rare autoimmune disease in which AChR autoantibodies trigger complement activation and cause damage to the neuromuscular junction. This study evaluated the therapeutic potential of an anti-C2 antibody in the rat passive transf…
Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.
Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder with substantial healthcare resource utilization (HRU) and high economic burden. This study evaluated HRU, costs, and predictors of high-cost events in adults with gMG, using data from VIVACITY-MG3. Post-hoc analyses used the…
Immune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series.
Immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events, including myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS). This syndrome poses notable management challenges and has high mortality rates. Due to limited data, its clinical features and optimal…
Infections and the neuromuscular junction: From direct neurotoxicity to immune-mediated dysfunction.
Infectious diseases and disorders of the neuromuscular junction (NMJ) are linked by complex and heterogeneous mechanisms that extend beyond direct pathogen-mediated injury. While some infectious agents can directly impair neuromuscular transmission, others may act as triggers of autoimmunity or cont…
Safety of Ravulizumab Use in Pregnancy: Insights from a Global Pharmacovigilance Analysis.
Ravulizumab, a second-generation terminal complement C5 inhibitor (engineered from eculizumab) is approved for the treatment of rare complement-mediated disorders paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuro…